Zn Supplementation in HIV Immunological Non Responders

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorParc de Salut Mar

About this trial

Zinc is an essential micronutrient crucial for the normal functioning of the human immune system. Zinc deficiency impairs immune function and increases infection risk, especially in vulnerable populations like people living with HIV. This project aims to study the role of zinc supplementation in improving immune response in HIV-infected individuals who are Immunological Non-Responders (INRs)-people who have not restored Cluster of differentiation 4 (CD4) T-cell counts despite receiving antiretroviral therapy (ART). INRs face a higher risk of opportunistic infections, non-HIV comorbidities due to high inflammation, and generally have a poorer prognosis. Zinc supports immune function by aiding in immune cell development, cytokine production, and maintaining mucosal barrier integrity.

Several studies have investigated zinc supplementation in HIV-infected individuals, showing significant increases in CD4 counts and a reduction in opportunistic infections. However, the doses used vary, and the results are sometimes contradictory. Our objective is to study whether zinc supplementation in INRs improves immune function, specifically by increasing CD4 counts, decreasing inflammation, and affecting other immune parameters.

This project involves a clinical trial where INRs will be randomly assigned to receive 75mg of elemental zinc daily (in the form of 3 zinc acetate tablets) along with their usual treatment or to continue their treatment without zinc supplements. We will assess whether zinc supplementation increases CD4 lymphocytes, reduces inflammation in INRs, and induces immune system changes. We will also investigate immune system functionality by measuring the presence of the Torque Teno Virus (TTV), a harmless virus, and see how zinc supplementation impacts its control by monitoring viral load changes.

Recent research by our group has demonstrated that zinc has both antiviral and anti-inflammatory effects. Zinc supplementation is generally safe and well-tolerated, with few adverse effects. Zinc is available in various forms, including gluconate, acetate, and sulfate. Although the recommended daily dose is 40mg, studies have shown that doses exceeding 80mg have been safely administered for over 10 years without side effects.

We have selected a 75mg daily dose of elemental zinc for several reasons. Studies that showed no effect used lower doses (15-20mg/day), and our research found that 75mg/day improved outcomes in acute viral infections like Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2). We believe previous failures to show zinc's efficacy were due to insufficient dosing. After extensive literature review, we concluded that 75mg daily is safe and likely to produce the desired effects.

Our goal is to demonstrate the efficacy of zinc as an immunomodulatory agent. If successful, this could be a simple and cost-effective way to improve the quality of life for many people. We would recommend its widespread use under medical supervision, particularly at the doses being studied.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

confirmed HIV infection;

18 years or older

Serum zinc levels less than 150ug/dl (normal range considered 75-150 ug/dl)

HIV-1 infection on stable ART for at least 3 months with cumulative ART duration of at least 6 months

Disqualifiers

Pregnancy

Lactation

Active infectious or inflammatory condition

Uncontrolled diabetes

Trial design

Design model

Parallel

Treatments tested in this trial

  • zinc acetate

    Dietary supplement

    Participants in Control group. They will continue the SoC + 3 tablets of placebo and participants in Zinc supplementation group. Tablets will be separated 12h (just in case the ART is based in Integrase Inhibitors (INSTI)) during supplementation for 16 weeks with 3 tablets of zinc (83mg Zinc acetate/tablet).

  • Placebo

    Other intervention

    participants in Control group. They will continue the SoC + 3 tablets of placebo. 3 tablets separated 12h from ART during 16 weeks

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: PlaceboPlacebo comparator 1 intervention
Group B: Zn SupplementationExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

CD4+ T-cell number change

CD4+ T-cell count (cells/ml)

Time frame
16 weeks

Secondary outcomes

1

Change in CD4+Tcell activation

change in % CD38+ CD4+ T-cell

Time frame
16 weeks
2

Change in CD8+Tcell activation

change in % CD38+ CD8+ T-cell

Time frame
16 weeks
3

Change in Quality of Life EuroQol-5D-3L

Quality of life changes through EuroQuality of life-5D-3L (EuroQol-5D-3D). Highest (best Quality of life) 1.minimum value (less or equal to 0-worse quality of life)

Time frame
16 weeks
4

Changes in Interleukin-6

Changes in Interleukin-6 (pg/mL)

Time frame
16 weeks

Other outcomes

1

Changes at week 24 CD4+ T-cell number change

Changes in total CD4+ T-cell count (cells/ml) 8 weeks after stopping supplementation.

Time frame
Week 24
2

Changes at week 24 CD4+Tcell activation

change in % CD38+ CD4+ T-cell at week 24

Time frame
Week 24
3

Changes at week 24 CD8+Tcell activation

change in % CD38+ CD8+ T-cell at week 24

Time frame
Week 24
4

Changes at week 24 in Quality of Life EuroQol-5D-3L

Quality of life changes through EuroQuality of life-5D-3L (EuroQol-5D-3D). Highest (best Quality of life) 1.minimum value (less or equal to 0-worse quality of life)

Time frame
Week 24

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Parc de Salut Mar

Lead sponsor

Hospital de Sabadell

Collaborator